A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
![Thumbnail](/bitstream/handle/internal/6250/Mannion%20et%20al.pdf.jpg?sequence=3&isAllowed=y)
View/ Open
Date
2024-05-15Author
Mannion, J
Gifford, V
Bellenie, B
Fernando, W
Ramos Garcia, L
Wilson, R
John, SW
Udainiya, S
Patin, EC
Tiu, C
Smith, A
Goicoechea, M
Craxton, A
Moraes de Vasconcelos, N
Guppy, N
Cheung, K-MJ
Cundy, NJ
Pierrat, O
Brennan, A
Roumeliotis, TI
Benstead-Hume, G
Alexander, J
Muirhead, G
Layzell, S
Lyu, W
Roulstone, V
Allen, M
Baldock, H
Legrand, A
Gabel, F
Serrano-Aparicio, N
Starling, C
Guo, H
Upton, J
Gyrd-Hansen, M
MacFarlane, M
Seddon, B
Raynaud, F
Roxanis, I
Harrington, K
Haider, S
Choudhary, JS
Hoelder, S
Tenev, T
Meier, P
Type
Journal Article
Metadata
Show full item recordAbstract
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a critical stress sentinel that coordinates cell survival, inflammation, and immunogenic cell death (ICD). Although the catalytic function of RIPK1 is required to trigger cell death, its non-catalytic scaffold function mediates strong pro-survival signaling. Accordingly, cancer cells can hijack RIPK1 to block necroptosis and evade immune detection. We generated a small-molecule proteolysis-targeting chimera (PROTAC) that selectively degraded human and murine RIPK1. PROTAC-mediated depletion of RIPK1 deregulated TNFR1 and TLR3/4 signaling hubs, accentuating the output of NF-κB, MAPK, and IFN signaling. Additionally, RIPK1 degradation simultaneously promoted RIPK3 activation and necroptosis induction. We further demonstrated that RIPK1 degradation enhanced the immunostimulatory effects of radio- and immunotherapy by sensitizing cancer cells to treatment-induced TNF and interferons. This promoted ICD, antitumor immunity, and durable treatment responses. Consequently, targeting RIPK1 by PROTACs emerges as a promising approach to overcome radio- or immunotherapy resistance and enhance anticancer therapies.
Collections
Subject
RIPK1
TLR3
TNF
anticancer immunity
cell death
immunotherapy
inflammation
interferon
necroptosis
radiotherapy
Research team
Cell Death and Immunity
Targeted Therapy
Language
eng
Date accepted
2024-04-25
License start date
2024-05-15
Citation
Immunity, 2024,
Publisher
Elsevier BV